

# Jennifer G Goldman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7121/jennifer-g-goldman-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

8,440  
citations

35  
h-index

79  
g-index

79  
ext. papers

10,515  
ext. citations

6.1  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
77	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 1689-707; quiz 1837	7	1968
76	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , <b>2017</b> , 89, 88-100	6.5	1691
75	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , <b>2012</b> , 27, 349-56	7	1373
74	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , <b>2011</b> , 26, 1814-24	7	527
73	Premotor and nonmotor features of Parkinson's disease. <i>Current Opinion in Neurology</i> , <b>2014</b> , 27, 434-41	7.1	195
72	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , <b>2020</b> , 94, 743-755	7.5	151
71	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 2501-7	7	124
70	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1217-1224	17.2	120
69	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 95-102	7	113
68	Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , <b>2015</b> , 30, 1657-63	7	107
67	Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. <i>Brain</i> , <b>2014</b> , 137, 849-59	11.2	103
66	αSynuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <i>Nature Communications</i> , <b>2020</b> , 11, 1875	17.4	102
65	The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , <b>2014</b> , 29, 608-21	7	89
64	Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?. <i>Movement Disorders</i> , <b>2015</b> , 30, 402-6	7	86
63	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , <b>2018</b> , 33, 208-218	7	80
62	Acceptability and Reliability of an Online Version of the MEPA III Screener IN Parkinson'S Participants (P01-010-19). <i>Current Developments in Nutrition</i> , <b>2019</b> , 3,	0.4	78
61	Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 1972-9	7	78

60	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , <b>2018</b> , 33, 282-288	7	78
59	Treatment of psychosis and dementia in Parkinson's disease. <i>Current Treatment Options in Neurology</i> , <b>2014</b> , 16, 281	4.4	76
58	Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 1129-36	7	76
57	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , <b>2017</b> , 32, 1056-1065	7	75
56	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinsons Disease</i> , <b>2018</b> , 4, 19	9.7	72
55	Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Movement Disorders</i> , <b>2008</b> , 23, 2248-50	7	66
54	βsynuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , <b>2016</b> , 79, 991-9	9.4	64
53	Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor. <i>Cerebral Cortex</i> , <b>2015</b> , 25, 4191-202	5.1	54
52	Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 806-11	3.6	50
51	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1471-89	7	50
50	Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2014</b> , 69, 1-14	7.5	47
49	Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. <i>Archives of Neurology</i> , <b>2004</b> , 61, 1280-4		44
48	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , <b>2016</b> , 31, 1619-1622	7	43
47	Parkinson's disease mild cognitive impairment: application and validation of the criteria. <i>Journal of Parkinsons Disease</i> , <b>2014</b> , 4, 131-7	5.3	42
46	Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. <i>Neurology</i> , <b>2017</b> , 88, 1265-1272	6.5	41
45	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , <b>2012</b> , 27, 727-34	7	39
44	Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , <b>2012</b> , 27, 248-53	7	38
43	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , <b>2016</b> , 31, 924-32	7	36

42	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , <b>2018</b> , 33, 503-510	7	33
41	Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 1135-9	3.6	33
40	White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. <i>Neurology</i> , <b>2018</b> , 91, e2244-e2255	6.5	31
39	An update expert opinion on management and research strategies in Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2009-24	4	29
38	Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Movement Disorders</i> , <b>2020</b> , 35, 1509-1531	7	25
37	Treatment of dystonia. <i>Clinical Neuropharmacology</i> , <b>2003</b> , 26, 102-8	1.4	25
36	Cognitive Impairment and Dementia in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , <b>2020</b> , 36, 365-377	3.8	24
35	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , <b>2018</b> , 33, 1750-1759	7	22
34	Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 11-22	7	21
33	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , <b>2019</b> , 34, 430-435	4.5	21
32	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , <b>2015</b> , 5, 425-43	2.8	19
31	The Effects of Dual-Task Cognitive Interference and Environmental Challenges on Balance in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 202-212	2.2	17
30	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , <b>2018</b> , 33, 528-536	7	16
29	High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. <i>Radiology</i> , <b>2019</b> , 291, 149-157	20.5	15
28	Treatment of Nonmotor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , <b>2020</b> , 38, 269-292	4.92	14
27	Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 585-9	5.3	14
26	Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation. <i>Movement Disorders</i> , <b>2013</b> , 28, 1462-3	7	13
25	Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. <i>Movement Disorders</i> , <b>2011</b> , 26, 1781-2	7	12

24	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 65, 178-183	3.6	11
23	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 137	9	10
22	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1760-1768	7	10
21	The effects of dual-task cognitive interference on gait and turning in Huntington's disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226827	3.7	9
20	Peripheral electrical stimulation to reduce pathological tremor: a review. <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2021</b> , 18, 33	5.3	8
19	New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. <i>Parkinson's Disease</i> , <b>2011</b> , 2011, 675630	2.6	7
18	Writer's cramp. <i>Toxicon</i> , <b>2015</b> , 107, 98-104	2.8	6
17	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , <b>2014</b> , 29, 1252-7	7	6
16	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 128, 367-382	9	3
15	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 23	9	2
14	Validation of an Online Screener, the Mediterranean Eating Pattern for Americans-III in Older Patients with Parkinson's Disease. <i>Journal of Nutrition in Gerontology and Geriatrics</i> , <b>2020</b> , 39, 30-43	2.1	2
13	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.. <i>Npj Parkinson's Disease</i> , <b>2022</b> , 8, 30	9.7	2
12	Reply To: Detection of Alpha-Synuclein in Saliva: The Importance of Preanalytical Assessment. <i>Movement Disorders</i> , <b>2018</b> , 33, 1031	7	1
11	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 805135	4.1	1
10	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 124	9	1
9	Twelve Drummers Drumming With Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , <b>2021</b> , 11, 6	2	1
8	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , <b>2018</b> , 33, 499-500	7	0
7	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 479-483	2.2	0

- 6 Creating a patient-centered guide to navigating cognitive change in Parkinson disease. *Alzheimer's and Dementia*, **2020**, 16, e041115 1.2
- 5 The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. *Alzheimer's and Dementia*, **2020**, 16, e042846 1.2
- 4 Shared imaging biomarkers across Alzheimer and Parkinson disease. *Alzheimer's and Dementia*, **2020**, 16, e046542 1.2
- 3 Huntington disease **2021**, 371-400.e14
- 2 Nonmotor problems in Parkinson disease **2021**, 234-248.e7
- 1 Parkinsonism **2021**, 82-120.e21